Unique ID issued by UMIN | UMIN000044272 |
---|---|
Receipt number | R000050563 |
Scientific Title | A randomised, double-blind, placebo-controlled crossover clinical trial on the effect of lactulose on improving the intestinal environment. |
Date of disclosure of the study information | 2021/05/20 |
Last modified on | 2022/12/08 14:36:44 |
A clinical trial on the effect of lactulose on improving the intestinal environment.
A clinical trial of lactulose.
A randomised, double-blind, placebo-controlled crossover clinical trial on the effect of lactulose on improving the intestinal environment.
A clinical trial on the effect of lactulose on improving the intestinal environment.
Japan |
Not applicable
Not applicable | Adult |
Others
NO
To verify the bifidobacteria growth effect over time when 4 g of lactulose is ingested.
Efficacy
Bifidobacterium occupancy in feces
Stool bacterial flora, stool bifidobacterial count, defecation frequency, the days of defecation, stool properties, defecation volume, strength of defecation, defecation time.
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
YES
Central registration
2
Treatment
Food |
Intake of lactulose 4g/day for 2 weeks
Intake of placebo for 2 weeks
20 | years-old | <= |
65 | years-old | > |
Male and Female
・Persons who defecate 3 to 7 days par week
・Persons with bifidobacteria in the intestines
1) Subjects with severe hepatic, renal, heart, gastrointestinal, cerebrovascular, endocrine, metabolic or infection diseases.
2) Subjects with the history of gastrointestinal resection.
3) Subjects with gastrointestinal dysfunction such as irritable bowel syndrome or inflammatory bowel disease.
4) Subjects who use medicines or supplements that may influence feces frequency; e.g. antibiotics, probiotics, laxatives, antidiarrheals, fibers.
5) Subjects with milk allergy or lactose intolerance.
6) Subjects who participate another study.
7) Subjects who are judged inappropriate for the study by the investigator or the physician.
36
1st name | Daisuke |
Middle name | |
Last name | Kawaguchi |
Megurodoori Gastrointestinal Surgery Internal Medicine Clinic
Doctor's department
153-0064
6-1-27 Shimo-Meguro, Meguro-Ku, Tokyo
03-3713-1117
info@meguro-ikamera.com
1st name | Yosuke |
Middle name | |
Last name | Inaba |
3H Clinical Trial Co., Ltd.
Patient Recruitment Group
171-0022
1-13-23 Minamiikebukuro, Toshima-ku, Tokyo
03-5985-0053
info@c-trial.com
Megurodoori Gastrointestinal Surgery Internal Medicine Clinic
Morinaga Milk Industry Co., LTD.
Profit organization
Japan Conference of Clinical Research
1-13-23 Minamiikebukuro, Toshima-ku, Tokyo
03-6868-7022
jccr-info@jccr.jp
NO
医療法人社団 一星会 目黒通り消化器外科・内科クリニック
2021 | Year | 05 | Month | 20 | Day |
https://doi.org/10.3390/microorganisms10091719
Published
https://doi.org/10.3390/microorganisms10091719
36
Ingestion of 4 g of lactulose for 3 days increased fecal bifidobacterial occupancy.
2022 | Year | 12 | Month | 08 | Day |
Healthy Japanese adult male and female
Refer to the paper
Refer to the paper
Refer to the paper
Completed
2021 | Year | 04 | Month | 30 | Day |
2021 | Year | 05 | Month | 13 | Day |
2021 | Year | 05 | Month | 21 | Day |
2021 | Year | 10 | Month | 27 | Day |
2022 | Year | 03 | Month | 18 | Day |
2022 | Year | 04 | Month | 07 | Day |
2022 | Year | 07 | Month | 22 | Day |
2021 | Year | 05 | Month | 20 | Day |
2022 | Year | 12 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050563
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |